Syndromes With Neonatal Salt Loss: Not Only Congenital Adrenal Hyperplasia Due to 21-hydroxylase Deficiency (21OH-ISC)

Key facts

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Principal Investigator

Federico Baronio

Enrollment

25 enrolled

Eligibility

1-35 years · All sexes

Timeline

2025 – 2026

Study locations (1)

• IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Congenital adrenal hyperplasia

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2, PHASE3NCT07159841
  A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)
  Crinetics Pharmaceuticals Inc.
• RECRUITINGPHASE3NCT07144163
  A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia
  Crinetics Pharmaceuticals Inc.
• RECRUITINGPHASE2NCT07187375
  Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old
  Neurocrine Biosciences
• RECRUITINGPHASE2NCT06712823
  An Extension Study to Evaluate Safety and Efficacy in Participants Treated With CRN04894
  Crinetics Pharmaceuticals Inc.
• RECRUITINGNANCT07099456
  Fertility And Sexual Function In CAH: CALLIOPE
  University of Roma La Sapienza
• RECRUITINGPHASE1, PHASE2NCT05669950
  A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia
  H. Lundbeck A/S
• RECRUITINGNCT06754423
  Electronic Registry of Male Patients With Congenital Adrenal Hyperplasia 21-hydroxylase Deficiency
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT04783181
  A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH)
  Adrenas Therapeutics Inc

See all trials for Congenital adrenal hyperplasia →